-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NLnZcn9MxCntEYJEeKkwPEe2yTbEECLU4rQlmuL9YkgKh5AHUCapKLccFG+7hME7 B5KX9LAsy6YFjTU6r5P6UA== 0001344213-10-000006.txt : 20100402 0001344213-10-000006.hdr.sgml : 20100402 20100401175046 ACCESSION NUMBER: 0001344213-10-000006 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506 FILED AS OF DATE: 20100402 DATE AS OF CHANGE: 20100401 EFFECTIVENESS DATE: 20100402 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Natrogen Therapeutics International, Inc. CENTRAL INDEX KEY: 0001344213 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-83126 FILM NUMBER: 10725934 BUSINESS ADDRESS: STREET 1: 315 EAST 68TH ST. CITY: NEW YORK STATE: NY ZIP: 10065 BUSINESS PHONE: 212-988-7490 MAIL ADDRESS: STREET 1: 315 EAST 68TH ST. CITY: NEW YORK STATE: NY ZIP: 10065 FORMER COMPANY: FORMER CONFORMED NAME: NATROGEN THERAPEUTICS INTERNATIONAL, INC DATE OF NAME CHANGE: 20100325 FORMER COMPANY: FORMER CONFORMED NAME: NATROGEN THERAPEUTICS INTERNATIONAL INC DATE OF NAME CHANGE: 20051114 D 1 primary_doc.xml X0603 D LIVE 0001344213 Natrogen Therapeutics International, Inc. 315 East 68th St. New York NY 10065 212-988-7490 DELAWARE NATROGEN THERAPEUTICS INTERNATIONAL, INC NATROGEN THERAPEUTICS INTERNATIONAL INC Corporation true Longgui Wang 45-35 166th St. Flusing NY 11358 Executive Officer Director Allen Tsao 24401 N. Windlake Road Windlake WI 53185 Director Simon Mencher 315 East 68th St. New York NY 10065 Executive Officer Director James P. McCarron Jr. 315 East 68th St. New York NY 10065 Director Basil Hanss 1725 York Avenue, Apt. 20B New York NY 10128 Director Richard Bartlett 315 East 68th St. New York NY 10065 Director Xiaomei Liu 315 East 68th St. New York NY 10065 Executive Officer Pharmaceuticals Decline to Disclose 06 false 2007-11-16 false true true false 0 375211 250000 125211 Includes the sale and issuance of 888 shares of Common Stock and a Warrant to purchase 444 shares of Common Stock, both at $281.69 per share. false 1 0 0 0 false Natrogen Therapeutics International, Inc. /s/ Longgui Wang Longgui Wang President 2010-04-01 -----END PRIVACY-ENHANCED MESSAGE-----